Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018
June 19 2018 - 4:01PM
Biogen (Nasdaq:BIIB) today announced it will host a live webcast
providing an overview of its efforts targeting acute ischemic
stroke on Thursday, June 28, 2018. The live webcast will be
from 8:00-9:00 a.m. ET with Michael Ehlers, M.D., Ph.D., executive
vice president, Research and Development, and Chirfi Guindo,
executive vice president, head of Global Marketing, Market Access
and Customer Innovation. To access the live webcast, please go to
the investors section of Biogen’s website at
www.biogen.com/investors. Following the live webcast, an
archived version of the call will be available on the website.
About Biogen At Biogen, our mission is clear:
we are pioneers in neuroscience. Biogen discovers, develops, and
delivers worldwide innovative therapies for people living with
serious neurological and neurodegenerative diseases. One of the
world’s first global biotechnology companies, Biogen was founded in
1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel
Prize winners Walter Gilbert and Phillip Sharp, and today has the
leading portfolio of medicines to treat multiple sclerosis; has
introduced the first and only approved treatment for spinal
muscular atrophy; and is focused on advancing neuroscience research
programs in Alzheimer’s disease and dementia, multiple sclerosis
and neuroimmunology, movement disorders, neuromuscular disorders,
pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen
also manufactures and commercializes biosimilars of advanced
biologics.
We routinely post information that may be important to investors
on our website at www.biogen.com. To learn more, please visit
www.biogen.com and follow us on social media – Twitter, LinkedIn,
Facebook, YouTube.
Contact:Karen JewellInvestor RelationsBiogen781.464.2442
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Sep 2023 to Sep 2024